scorecardresearch
Add as a preferred source on Google
Friday, January 23, 2026
TopicCDSCO

Topic: CDSCO

Use nimesulide only after exhausting first-line options—expert panel under drug regulator CDSCO

Last year, an ICMR panel even considered recommending all-India ban on popular painkiller amid concerns it could cause liver damage, which could turn life-threatening in some cases.

As CDSCO lifts suspension on eye drops designed to replace reading glasses, makers eye June launch

Doctors caution that the drug should be used only under strong and regular supervision of an ophthalmologist.

No local clinical trial waiver despite change in rules, drugmakers knock on health ministry’s door

Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved in select countries by means of local clinical trials waiver.

Antibiotics launched in India will soon need CDSCO nod as drug resistance emerges as silent killer

In 2019, bacterial antimicrobial resistance killed between 3 lakh and 10.4 lakh people in India, according to a Lancet report.

Why a govt-appointed panel has recommended a complete ban on popular painkiller nimesulide

First launched in Italy in 1985, Nimesulide is available in India under brand names like Nimuwin, Nimutab, Nimopen, Nisulid, Nimdase, Nodard Plus, Nicip, Nimcap, Nicip-P and Nimupain.

Govt says no plan to ban heartburn drug ranitidine, carcinogenic impurities within safe limits

In 2019, evidence showed that an impurity in drug degrades over time to form probable carcinogenic compound. Ranitidine is sold as heartburn medicine under names Rantac, Aciloc & Zinetac.

Drug regulator considers making central nod mandatory for all antibiotics in India, even existing ones

This new proposal, being considered by CDSCO, comes in response to concerns over antimicrobial resistance emerging as a massive public health challenge across the globe, including in India.

India has a substandard, fake drugs problem. Lack of recall law, scrutiny is making matters worse

Underlining need for more accountability, experts also stress that govt data does not include fixed dose combination drugs, which account for over 40% of drugs sold in India.

Eye drop’s claim to replace glasses cost it the launch & sale nod. The controversy & safety concerns

Regulatory approval to Entod Pharma for PresVu, meant to treat presbyopia, was revoked as the firm marketed it as a 'replacement for reading glasses' & due to possible health risks.

‘Unauthorised promotion’, risk of unsafe use: Why CDSCO revoked nod for eye drops to replace glasses

Drugs Controller General of India, who heads CDSCO, says Entod pharma failed to reply satisfactorily to queries raised. Entod to challenge suspension of approval.

On Camera

Controversial dog-walker IAS Sanjeev Khirwar is back in Delhi. What happened to his wife?

In 2022, athletes claimed they were asked to wind up training early at Thyagraj Stadium so that the IAS couple could walk their dog. Then came the memes and public outrage.

IndiGo profit plunges 78% as Dec meltdown with 3k flight cancellations takes a toll

Net income for InterGlobe Aviation Ltd slipped 78 percent to Rs 5.5 billion for the three months ended Dec 31 compared with the year-ago period.

Rafale saga: 25 yrs of detours, deadlocks & political hesitation. Now IAF getting what it always wanted

Instead of buying more Mirages outright in early 2000s, the requirement was tweaked in favour of a medium-weight, multi-role fighter with Mirage-like performance. 

Pakistan se azaadi. Grow up India, stop giving it prime real estate in your psyche

Pakistan not only has zero chance of catching up with India in most areas, but will inevitably see the gap rising. Its leaders will offer its people the same snake oil in different bottles.